Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2008

Novo Nordisk to Pay $87M for Emisphere’s Drug Delivery Technology

  • Novo Nordisk has obtained a license to use Emisphere Technologies’ eligen carrier technology to advance its type 2 diabetes program. The platform will be used in developing and commercializing oral formulations of GLP-1 receptor agonists.

    The agreement includes at least $87 million in product development and sales milestone payments. Of this, $10 million will be the minimum first year payment. Emisphere will also earn royalties.

    Novo Nordisk will be responsible for the development and commercialization of the product candidates. The firms report that they have been collaborating since 2007 on early-stage preclinical research that confirmed the utility of Emisphere's carriers to provide bioavailable oral formulations of GLP-1 receptor agonists.

    Novo Nordisk also obtained an option to develop other oral formulations of  compounds using eligen. The technology, according to the companies, makes it possible to deliver a therapeutic molecule without altering its chemical form or biological integrity.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »